Acquired Company

Merck acquired Verona Pharma on 10/7/2025 for $107 per ADS, representing a total transaction value of about $10 billion.

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC. Show more

3 More London Riverside, London, SE1 2RE, United Kingdom

https://www.veronapharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

9.085B

52 Wk Range

$31.60 - $106.93

Previous Close

$106.91

Open

$106.91

Volume

N/A

Day Range

$106.91 - $106.91

Enterprise Value

8.992B

Cash

438M

Avg Qtr Burn

-18.12M

Insider Ownership

4.89%

Institutional Own.

92.23%

Qtr Updated

06/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ohtuvayre (Ensifentrine-nebulized) Details Chronic obstructive pulmonary disease (COPD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine + glycopyrrolate Details Chronic obstructive pulmonary disease (“COPD”)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Nebulized) Details Non-cystic fibrosis bronchiectasis (bronchiectasis)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Nebulized) Details Lung disease, Asthma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ensifentrine (Inhaled) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.